Logo image of CBIO

CATALYST BIOSCIENCES INC (CBIO) Stock Fundamental Analysis

NASDAQ:CBIO - Nasdaq - US14888D2080 - Common Stock - Currency: USD

0.5113  -0.01 (-2.65%)

After market: 0.5406 +0.03 (+5.73%)

Fundamental Rating

1

CBIO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. CBIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CBIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CBIO had negative earnings in the past year.
CBIO had a negative operating cash flow in the past year.
In the past 5 years CBIO always reported negative net income.
CBIO had a negative operating cash flow in each of the past 5 years.
CBIO Yearly Net Income VS EBIT VS OCF VS FCFCBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

CBIO has a Return On Assets of -444.02%. This is amonst the worse of the industry: CBIO underperforms 97.85% of its industry peers.
CBIO has a worse Return On Equity (-1257.95%) than 85.97% of its industry peers.
Industry RankSector Rank
ROA -444.02%
ROE -1257.95%
ROIC N/A
ROA(3y)-82.09%
ROA(5y)-65.26%
ROE(3y)-119.61%
ROE(5y)-92.94%
ROIC(3y)N/A
ROIC(5y)N/A
CBIO Yearly ROA, ROE, ROICCBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBIO Yearly Profit, Operating, Gross MarginsCBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100K -200K -300K

More info and screens

5

2. Health

2.1 Basic Checks

CBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CBIO has more shares outstanding
There is no outstanding debt for CBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CBIO Yearly Shares OutstandingCBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
CBIO Yearly Total Debt VS Total AssetsCBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -60.55, we must say that CBIO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -60.55, CBIO is not doing good in the industry: 97.52% of the companies in the same industry are doing better.
There is no outstanding debt for CBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -60.55
ROIC/WACCN/A
WACC10.5%
CBIO Yearly LT Debt VS Equity VS FCFCBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.88 indicates that CBIO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.88, CBIO is doing worse than 72.44% of the companies in the same industry.
A Quick Ratio of 2.88 indicates that CBIO has no problem at all paying its short term obligations.
CBIO's Quick ratio of 2.88 is on the low side compared to the rest of the industry. CBIO is outperformed by 71.12% of its industry peers.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
CBIO Yearly Current Assets VS Current LiabilitesCBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CBIO have decreased strongly by -465.60% in the last year.
The Revenue for CBIO has decreased by -100.00% in the past year. This is quite bad
CBIO shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.89% yearly.
EPS 1Y (TTM)-465.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-556.25%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-4.89%
Sales Q2Q%N/A

3.2 Future

CBIO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -26.45% yearly.
CBIO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-117.39%
EPS Next 2Y-42.57%
EPS Next 3Y-26.45%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CBIO Yearly Revenue VS EstimatesCBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
CBIO Yearly EPS VS EstimatesCBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBIO Price Earnings VS Forward Price EarningsCBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBIO Per share dataCBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

CBIO's earnings are expected to decrease with -26.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.57%
EPS Next 3Y-26.45%

More info and screens

0

5. Dividend

5.1 Amount

CBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CATALYST BIOSCIENCES INC

NASDAQ:CBIO (10/30/2023, 8:00:01 PM)

After market: 0.5406 +0.03 (+5.73%)

0.5113

-0.01 (-2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-26 2023-10-26/amc
Earnings (Next)03-28 2024-03-28/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners1.01%
Ins Owner Change0%
Market Cap19.42M
Analysts43.33
Price Target16.32 (3091.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend1.3
Dividend Growth(5Y)N/A
DP-28.85%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.65%
Min EPS beat(2)-37.25%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)26.24%
Min EPS beat(4)-37.25%
Max EPS beat(4)114.01%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1400%
EPS NQ rev (3m)-1100%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.52
P/tB 5.52
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -444.02%
ROE -1257.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.09%
ROA(5y)-65.26%
ROE(3y)-119.61%
ROE(5y)-92.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z -60.55
F-Score2
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)196.44%
Cap/Depr(5y)217.86%
Cap/Sales(3y)4.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-465.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-556.25%
EPS Next Y-117.39%
EPS Next 2Y-42.57%
EPS Next 3Y-26.45%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-4.89%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y69.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y84.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y84.83%
OCF growth 3YN/A
OCF growth 5YN/A